To demonstrate NATS efficacy, we thus chose a well-characterized antibody, trastuzumab (Herceptin) used therapeutically for targeting cancer cells overexpressing the HER-2/Neu member of the EGFR family [33]. This evidence concerns the gene ERBB2 and cancer.